TSS
VYGR icon

Two Sigma Securities’s Voyager Therapeutics VYGR Stock Holding History

Two Sigma Securities’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,268
Closed -$86K – 2889
2022
Q1 		$86K Buy
+11,268
New +$50.3K ﹤0.01% 1823

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Securities's VYGR Position: Q2 2022 in Review

Two Sigma Securities sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 11,268 shares — an estimated $86K sold.

Two Sigma Securities first reported a position in VYGR in Q1 2022 and held it in 1 quarter. The position peaked at $86K in Q1 2022. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

  • Two Sigma Securities reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Securities sold 11,268 Voyager Therapeutics shares in Q2 2022, an estimated $86K.
  • Two Sigma Securities first reported a position in Voyager Therapeutics in Q1 2022 and held it in 1 quarter.
  • Two Sigma Securities's Voyager Therapeutics position peaked at $86K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on Two Sigma Securities's 13F filing for Q2 2022, filed 15 Aug 2022.